GLENMARK logo

Glenmark Pharmaceuticals

F&O
GLENMARK·NSE·
2,455.00 -25.00 (-1.01%)
Market Cap69740.22 Cr
PE Ratio50.87
Volume6,72,546
Day High - Low2494.90 - 2455.00
52W High-Low2537.60 - 1792.60
DocStoX Score
5.3/10
Weak
Fair Value
Sign in to see
ROE
30.50%
Strong
P/E
50.87x
Expensive
Debt / Equity
0.00
Low
Industry
Healthcare
Pharmaceuticals
Overall View
Mixed

Price performance

NIFTY 200NIFTY 500NIFTY MIDCAP 150
Day2455
2495
52W1793
2538
DocStoX take

Supported by quality (8.1) and momentum (7.5), but held back by valuation (0.0). Quality looks strong at 8.1, but that is offset by valuation at 0.0. We are calling it Mixed rather than resolving the conflict for you.

DocStoX score

Low confidence
5.3
/10
Weak
Quality
Excellent
ROE 30.5%
Valuation
Expensive
P/E 50.9×
Growth
Slow
Revenue +9.2% 5Y CAGR
Risk
Moderate
D/E 0.00
Momentum
Strong
89% of 52-week range

At a glance

Market Cap
₹69,740 Cr
52W High / Low
₹2538 / ₹1793
Dividend Yield
0.20%
Promoter Holding
46.65%
EPS (TTM)
₹48.26
Book Value
₹372.00

Key highlights

  • Capital works hard — ROCE 40%
  • Strong returns on equity (31%)
  • Low leverage — D/E 0.00
  • Valuation is weak (0.0/10)
3 Positives1 Watchout

Growth

Financials

Shareholding

Technicals

Peers

News

Forecasts

About the company

More data

Filings, corporate actions and ownership detail — opened on demand.

More Healthcare stocks · Pharmaceuticals

GLENMARK PHARMACEUTICALS peers in Healthcare

Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.